Background: The aim of this study was to characterize the demographic characteristics and
investigate the cost of a publicly funded system, the Ontario Trillium Drug Program (TDP), for …

Background The financial impact of cancer medicines on health systems is not well known.
We describe temporal trends in expenditure on cancer medicines within the single-payer …

e16516 Background: Access to costly new cancer drug treatments is a problem in many
countries. In Canada, health care funding is a provincial responsibility and there could be …

Canada lacks a national drug insurance plan. The home province or territory of a patient
determines which cancer drugs are available on the public formulary, who is eligible for …

6625 Background: High costs of oncology drugs have threatened the affordability of cancer
care. Previous research using data from privately insured non-elderly cancer patients (pts) …

In 2011, health care spending in the United States was estimated at $2.7 trillion, 1 making it
the sixth largest economy in the world, larger than the national budget of France. National …

Abstract Background The Medicare Modernization Act (MMA) reduced reimbursement for
many antineoplastics delivered in outpatient settings, altering practice patterns for some …

e17538 Background: Clinical pathways can change practice patterns that result in benefits
for all stakeholders; however, their impact on other regional payers is unknown. Will a first-to …

Objectives In light of the current debate on the use value and potential impact of comparative
effectiveness research on patient access, it may prove insightful to compare a health-care …

Objectives Some targeted therapies have improved survival and overall quality of cancer
care generally, but these increasingly expensive medicines have led to increases in …